Search - tctmd.com

Displaying 1 - 20 of 6720

Sort: Relevancy | Date

News Daily News

Expanding Ambulatory Monitoring After TAVI May Prevent Serious Events

L.A. McKeown

May 12, 2026

News Daily News

Three in 10 AVRs in Adults Younger Than 65 Are Transcatheter

Yael L. Maxwell

May 08, 2026

News Daily News

Proportion of Women Undergoing TAVI for Aortic Stenosis Declining in US

Michael O'Riordan

May 08, 2026

News Daily News

GLP-1 Drugs May Lower CV Risk in TAVI Patients With Diabetes or Obesity

Yael L. Maxwell

April 29, 2026

News Featured Fellow

Ting-Yu (Tintin) Wang, MD

Yael L. Maxwell

April 09, 2026

News Conference News ACC 2026

Novel Cerebral Protection Device Matches Up Well With Sentinel in TAVI

Todd Neale

March 30, 2026

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

News Daily News

Benefits of Early SAVR for Asymptomatic Aortic Stenosis Persist a Decade On

Todd Neale

March 26, 2026

News Daily News

FDA Approves JenaValve’s Trilogy for Aortic Regurgitation

Michael O'Riordan

March 23, 2026

News Conference News CRT 2026

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

L.A. McKeown

March 19, 2026

News Daily News

Echocardiographic Surveillance of AS Doesn’t Measure Up to Guidelines

Caitlin E. Cox

March 18, 2026

News Conference News CRT 2026

PARTNER 3: TAVI and SAVR Matched for Health Status at 7 Years

L.A. McKeown

March 17, 2026

News Conference News CRT 2026

SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

L.A. McKeown

March 16, 2026

Presentation THT 2026

Over-Reliance on echocardiogram: A story of missed TAVR failure aortic regurgitation.

Presenter: Norman Zheng

March 04, 2026

Presentation THT 2026

Predictors of Structural Remodeling After TAVR in Moderate Aortic Stenosis with Heart Failure with Reduced Ejection Fraction

Presenter: Afek Kodesh

March 03, 2026

Presentation THT Abstracts 2026

Successful ViV-TAVR on a Deteriorated Mosaic Bioprosthetic Valve: A Promising Alternative to High-Risk Surgical Repair

Presenter: Rani Marhaba

March 02, 2026

Presentation THT Abstracts 2026

Veno-Arterial ECMO as a Bridge to Therapeutic TAVR in a Patient With Refractory Cardiogenic Shock Secondary to Aortic Stenosis

Presenter: Rani Marhaba

March 02, 2026

News Conference News EAPCI 2026

AVR in Asymptomatic AS: Look to the ‘Sweet Spot’ for Timing

Caitlin E. Cox

February 25, 2026

News Daily News

Higher Reintervention Risk With TAVI Emerges at 6 to 7 Years in Evolut Low Risk Trial

Michael O'Riordan

February 19, 2026

News Conference News STS 2026

‘Concerning’ Trends Seen in Aortic Stenosis-Related Mortality: CDC WONDER

Yael L. Maxwell

February 10, 2026

Advertisement

Expanding Ambulatory Monitoring After TAVI May Prevent Serious Events

Three in 10 AVRs in Adults Younger Than 65 Are Transcatheter

Proportion of Women Undergoing TAVI for Aortic Stenosis Declining in US

GLP-1 Drugs May Lower CV Risk in TAVI Patients With Diabetes or Obesity

Ting-Yu (Tintin) Wang, MD

Novel Cerebral Protection Device Matches Up Well With Sentinel in TAVI

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Benefits of Early SAVR for Asymptomatic Aortic Stenosis Persist a Decade On

FDA Approves JenaValve’s Trilogy for Aortic Regurgitation

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

Echocardiographic Surveillance of AS Doesn’t Measure Up to Guidelines

PARTNER 3: TAVI and SAVR Matched for Health Status at 7 Years

SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

Over-Reliance on echocardiogram: A story of missed TAVR failure aortic regurgitation.

Predictors of Structural Remodeling After TAVR in Moderate Aortic Stenosis with Heart Failure with Reduced Ejection Fraction

Successful ViV-TAVR on a Deteriorated Mosaic Bioprosthetic Valve: A Promising Alternative to High-Risk Surgical Repair

Veno-Arterial ECMO as a Bridge to Therapeutic TAVR in a Patient With Refractory Cardiogenic Shock Secondary to Aortic Stenosis

AVR in Asymptomatic AS: Look to the ‘Sweet Spot’ for Timing

Higher Reintervention Risk With TAVI Emerges at 6 to 7 Years in Evolut Low Risk Trial

‘Concerning’ Trends Seen in Aortic Stenosis-Related Mortality: CDC WONDER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content